Literatura naukowa dotycząca Saccharomyces boulardii

Niektóre materiały mogą być objęte płatnym dostępem, za utrudnienia przepraszamy.

1.       World Gastroenterology Organisation Practice Guideline: Probiotics and prebiotics. (2017)

https://www.worldgastroenterology.org/UserFiles/                                file/guidelines/probiotics-and-prebiotics-english-2017.pdf

2.       H. Szajewska, J. Mrukowicz (2005) Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther; 22:365-72

3.       M. Guslandi, G. Mezzi, M. Sorghi, P. A. Testoni (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Did Dis Sci; 45: 1462-4

4.       M. Can, B. A. Besirbellioglu, I- Y. Avci et al. (2006) Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit; 12:PI19-22

5.       M. Guslandi, P. Giollo, P. A. Testoni (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol; 15:697-8

6.       L. V. McFarland (2006) Meta-analysis of probiotica for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol; 101:812-22

7.       Christina M. Surawicz (2003) Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Bet Practice & Research Clinical Gastroenterology Vol. 17, No. 5, p. 775-783

8.       Lynne V. McFarland, PhD; Christina M Surawicz, MD; Richard N. Greenberg, et al. (1994) A Randomized Placebo-Controlled Trial of Saccharomyces boulardii in Combination with Standard Antibiotics for Clostridium difficile Disease. JAMAJune 22/29, Vol. 271, No 24

9.       S. Ducluzeau & P. Raibaud (1981) Les interactions bactériennes dans le tube digestif. Rev. sci. tech. Epiz., 8 (2), p.291-311

https://pdfs.semanticscholar.org/2223/fc0ac3400bb253f1870fee0fe16e25a31013.pdf

10.   Yvan Vandenplas (1999) Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: Yeasts. Clin Microbiol Infect; 5 p. 389-395

11.   E. Camarri, A. Belvisi, G. Guidoni et al. (1981) A Double-Blind Comparison of Two Different Treatments for Acute Enteritis in Adults. Chemotherapy Vol. 27, p. 466-470

12.   J. P. Buts, P. Bernasconi, C. Dive (1990) Stimulation of secretory IgA and secretory component immunoglobulins in small interstine of rats treated with Saccharomyces boulardii. Dig Dis Sci. Feb; 35(2):251-256

13.   C. Pothoulakis, C. P. Kelly, M. A. Joshi, N. Gao, C. J. O´Keane, I. Castagliuolo, J. T. Lamont (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin: A binding and enterotoxicity in rat ileum. Gastroenterology;104(4): 1108-1115

14.   I.Castagliuolo, M. F. Riegler, L. Valenik, J. T. Lamont, C. Pothoulakis (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. Jan; 67(1): 302-307

15.   G. Dalmasso, F. Cottrez, V. Imbert, P. Lagadec, J-F. Peyron, P. Rampal, D. Czerucka, H. Groux. (2006) Saccharomyces boulardii Inhibits Inflammatory Bowel Disease by Trapping T Cells in Mesenteric Lymph Nodes. Gastroeneterology131: 1812-1825

16.   J. L. Benjamin et al. (2010) No clinical benefit of prebiotics in the treatment of active Crohn’s Disease: A double-blind, randomised, placebo-controlled trial. Digestive Disease Week, absract T2020

17.   T. J. Kaptchuk et al. (2010) Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLoS One; 5: e15591

18.   P. Munoz, E. Bouza, M. Cuenca-Estrella et al. (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis;40: 1625-34

19.   J. Muller, N. Remus, K. H. Harms (1995) Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses; 38:119-23

20.   Choi CH, Jo SY, Park HJ, Chang SK, Byeon J-S, Myung S-J (2011) A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol Sep;45(8):679–83.

21.   Szajewska H, Skórka A (2009) Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther.1;30(9):960–1.

22.   Szajewska H, Horvath A, Kołodziej M (2015) Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. Jun;41(12):1237–45.

23.   de Wit MA, A. M. Hoogenboom-Verdegaal, E. S. Goosen, M. J. Sprenger, M. W. Borgdorff (2000) A population based longitudinal study on the incidence and disease burden of gastyroenteritis and Campylobacter and Salmonella infection in four regions of the Netherlands. Eur J Epidemiol.; 16(8): 713-718

https://www.ncbi.nlm.nih.gov/pubmed/11142498